Rate Video

EHA 2020 | Myeloma CAR-T update with Nina Shah

Nina Shah • 8 Jun 2020

Multiple Myeloma bb2121 CAR-T JCARH125 JNJ-4528

Nina Shah, MD, of the University of California, San Francisco, CA, discusses the advent of BCMA CAR-T therapy in multiple myeloma, highlighting data from the KarMMA trial (NCT03361748), Janssen’s BCMA CAR-T Therapy JNJ-4528, and JCARH125 (NCT03430011). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Exciting new developments in multiple myeloma

Daniel Auclair et al. • 18 Oct 2017

NKTR-255 in multiple myeloma and NHL

Nina Shah • 10 Dec 2021

10 years of researching NK-cells for MM treatment

Nina Shah • 1 Jun 2018

T-Cell Engagers: targets, challenges and opportunity

Hermann Einsele et al. • 27 Mar 2022

Related Videos

Updates from the LocoMMotion study

Hermann Einsele • 11 Jun 2022

Safety and efficacy of teclistamab in patients with triple-class exposed R/R myeloma

Hermann Einsele • 11 Jun 2022

Safety and efficacy of REGN5458 in patients with relapsed/refractory (R/R) multiple myeloma

Joshua Richter • 11 Jun 2022

Updated results from CARTITUDE-1

Yi Lin • 11 Jun 2022